Title:
PREDICTIVE BIOMARKER FOR HYPOXIA-ACTIVATED PRODRUG THERAPY
Document Type and Number:
Japanese Patent JP2018052956
Kind Code:
A
Abstract:
PROBLEM TO BE SOLVED: To provide a predictive biomarker for hypoxia-activated prodrug therapy.SOLUTION: A method for treating cancer in a patient comprises the steps of measuring a CA-IX protein or RNA level in a sample isolated from the patient, and administering a hypoxia-activated prodrug to the patient if the measured level is equal to or greater than a predetermined value, or administering a cancer therapy other than a therapy comprising administration of a hypoxia-activated prodrug if the measured level does not exceed the predetermined value.SELECTED DRAWING: None
Inventors:
CHARLES HART
Application Number:
JP2017214327A
Publication Date:
April 05, 2018
Filing Date:
November 07, 2017
Export Citation:
Assignee:
THRESHOLD PHARMACEUTICALS INC
International Classes:
A61K45/00; A61P35/00; A61P43/00; G01N33/573
Attorney, Agent or Firm:
Yoshinori Hosoda
Previous Patent: A manufacturing method of acrylic acid
Next Patent: The new Regulin method and a constituent for dealing with cardiovascular disease
Next Patent: The new Regulin method and a constituent for dealing with cardiovascular disease